AAMU
BIO icon

Amundi Asset Management US’s Bio-Rad Laboratories Class A BIO Stock Holding History

Amundi Asset Management US’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$23M Buy
40,230
+8,743
+28% +$5.18M 0.02% 630
2020
Q4 		$18.4M Buy
31,487
+13,700
+77% +$7.8M 0.02% 657
2020
Q3 		$9.17M Buy
17,787
+8,136
+84% +$4.12M 0.01% 761
2020
Q2 		$4.36M Buy
9,651
+1,902
+25% +$839K 0.01% 908
2020
Q1 		$2.72M Buy
7,749
+179
+2% +$65.8K ﹤0.01% 880
2019
Q4 		$2.8M Buy
7,570
+6,428
+563% +$2.27M ﹤0.01% 1056
2019
Q3 		$380K Sell
1,142
-1,029
-47% -$336K ﹤0.01% 1364
2019
Q2 		$679K Buy
+2,171
New +$650K ﹤0.01% 1318
2018
Q4 		– Sell
-102,500
Closed -$32.1M – 1602
2018
Q3 		$32.1M Sell
102,500
-1,699
-2% -$527K 0.04% 401
2018
Q2 		$30.1M Buy
104,199
+1,672
+2% +$462K 0.04% 399
2018
Q1 		$25.6M Buy
+102,527
New +$26.1M 0.04% 416
2016
Q4 		– Sell
-5,009
Closed -$821K – 533
2016
Q3 		$821K Sell
5,009
-11,196
-69% -$1.7M ﹤0.01% 525
2016
Q2 		$2.32M Hold
16,205
– – 0.01% 494
2016
Q1 		$2.21M Sell
16,205
-434
-3% -$57K 0.01% 491
2015
Q4 		$2.31M Buy
16,639
+434
+3% +$60.2K 0.01% 488
2015
Q3 		$2.18M Sell
16,205
-3,281
-17% -$472K 0.01% 516
2015
Q2 		$2.93M Sell
19,486
-23,358
-55% -$3.34M 0.01% 525
2015
Q1 		$5.79M Sell
42,844
-8,466
-16% -$1.05M 0.02% 436
2014
Q4 		$6.19M Hold
51,310
– – 0.02% 418
2014
Q3 		$5.82M Hold
51,310
– – 0.02% 428
2014
Q2 		$6.14M Hold
51,310
– – 0.02% 426
2014
Q1 		$6.57M Sell
51,310
-11,162
-18% -$1.43M 0.03% 416
2013
Q4 		$7.72M Hold
62,472
– – 0.03% 382
2013
Q3 		$7.34M Sell
62,472
-1,000
-2% -$118K 0.03% 391
2013
Q2 		$7.12M Buy
+63,472
New +$7.45M 0.03% 383

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Amundi Asset Management US's BIO Position: Q1 2021 in Review

Amundi Asset Management US increased its Bio-Rad Laboratories Class A (BIO) stake by 28% in Q1 2021, buying an estimated $5.18M and bringing the position to 40,230 shares worth $23M. The position accounts for 0.02% of the portfolio, ranked #630.

Amundi Asset Management US first reported a position in BIO in Q2 2013 and has held it in 25 quarters since. The position peaked at $32.1M in Q3 2018. 492 funds tracked by Wall St. Rank hold BIO as of Q1 2021.

  • Amundi Asset Management US held 40,230 shares of Bio-Rad Laboratories Class A worth $23M as of Q1 2021.
  • Amundi Asset Management US bought 8,743 Bio-Rad Laboratories Class A shares in Q1 2021, an estimated $5.18M.
  • Bio-Rad Laboratories Class A made up 0.02% of Amundi Asset Management US's portfolio in Q1 2021, its #630 holding.
  • Amundi Asset Management US first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 25 quarters since.
  • Amundi Asset Management US's Bio-Rad Laboratories Class A position peaked at $32.1M in Q3 2018.
  • 492 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.